Observational studyPloS one2017

Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients.

Alexandre Guilhem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.